Literature DB >> 23417775

Elevated lipogenesis and diminished cholesterol synthesis in patients with hepatitis C viral infection compared to healthy humans.

Jennifer E Lambert1, Vincent G Bain, Edmond A Ryan, Alan B R Thomson, Michael T Clandinin.   

Abstract

UNLABELLED: Hepatitis C virus (HCV) exerts a profound influence on host lipid metabolism. It has been suggested that the synthesis of both fatty acids (FA) and cholesterol is dysregulated in HCV but this has not been directly quantified in humans. The purpose of this study was to measure lipogenesis and cholesterol synthesis using stable isotopes in patients with HCV (n = 5) and healthy control (n = 9) subjects recruited from the University of Alberta hospital. Blood samples were taken at fasting (0 and 24 hours) and after meals over the day to mimic typical food consumption and postprandial metabolism. Isolation of free cholesterol (FC), cholesteryl ester (CE), and triglyceride (TG) from plasma and very low-density lipoproteins (VLDL) was used to measure FA and cholesterol synthesis using deuterium uptake and isotope ratio mass spectrometry. FA composition was analyzed by gas chromatography. VLDL-TG levels of polyunsaturated fatty acids (PUFA), including linoleic and linolenic acid, were lower in HCV compared to control (P < 0.05 for both). Fasting hepatic lipogenesis was significantly higher in HCV (2.80 ± 0.55%) compared to control (1.19 ± 0.27%; P = 0.03). Conversely, fasting whole-body synthesis of FC (HCV 1.64 ± 0.28% versus control 8.78 ± 1.59%) and CE (HCV 0.26 ± 0.08% versus control 1.92 ± 0.25%), as well as hepatic FC synthesis (HCV 1.68 ± 0.26% versus control 8.12 ± 0.77%) was lower in HCV (P < 0.001 for all).
CONCLUSION: These data provide evidence that lipogenesis is elevated while cholesterol synthesis is impaired in HCV, supporting previous findings from cellular and animal models. Low PUFA levels combined with elevated lipogenesis suggests a role for dietary PUFA supplementation in HCV patients.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23417775     DOI: 10.1002/hep.25990

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  22 in total

1.  The strange and critical intersection of hepatitis C and lipoprotein metabolism: "C-zing" the oil.

Authors:  Stephen Caldwell; Kyle L Hoehn; Young S Hahn
Journal:  Hepatology       Date:  2012-12-12       Impact factor: 17.425

Review 2.  Metabolic and Cardiovascular Complications in HIV/HCV-Co-infected Patients.

Authors:  Roger Bedimo; Oladapo Abodunde
Journal:  Curr HIV/AIDS Rep       Date:  2016-12       Impact factor: 5.071

Review 3.  Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen.

Authors:  Amedeo Lonardo; Luigi Elio Adinolfi; Luciano Restivo; Stefano Ballestri; Dante Romagnoli; Enrica Baldelli; Fabio Nascimbeni; Paola Loria
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 4.  Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes.

Authors:  Tracey G Simon; Adeel A Butt
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742

Review 5.  Mechanisms of intrahepatic triglyceride accumulation.

Authors:  Claudia Ress; Susanne Kaser
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

6.  Hepatitis C Virus-Induced Degradation of Cell Death-Inducing DFFA-Like Effector B Leads to Hepatic Lipid Dysregulation.

Authors:  Emily M Lee; Ali Alsagheir; Xianfang Wu; Christy Hammack; John McLauchlan; Noriyuki Watanabe; Takaji Wakita; Norman M Kneteman; Donna N Douglas; Hengli Tang
Journal:  J Virol       Date:  2016-03-28       Impact factor: 5.103

Review 7.  Hepatitis C Virus Uses Host Lipids to Its Own Advantage.

Authors:  Malgorzata Sidorkiewicz
Journal:  Metabolites       Date:  2021-04-27

8.  Inhibition of Long Noncoding RNA Linc-Pint by Hepatitis C Virus in Infected Hepatocytes Enhances Lipogenesis.

Authors:  Mousumi Khatun; Subhayan Sur; Robert Steele; Ranjit Ray; Ratna B Ray
Journal:  Hepatology       Date:  2021-05-02       Impact factor: 17.298

9.  Chaperone-Mediated Autophagy Targets IFNAR1 for Lysosomal Degradation in Free Fatty Acid Treated HCV Cell Culture.

Authors:  Ramazan Kurt; Partha K Chandra; Fatma Aboulnasr; Rajesh Panigrahi; Pauline Ferraris; Yucel Aydin; Krzysztof Reiss; Tong Wu; Luis A Balart; Srikanta Dash
Journal:  PLoS One       Date:  2015-05-11       Impact factor: 3.240

10.  A comparative study of serum lipid contents in pre and post IFN-alpha treated acute hepatitis C patients.

Authors:  Sadia Qamar Arain; Farah Naz Talpur; Naseem Aslam Channa
Journal:  Lipids Health Dis       Date:  2015-09-24       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.